# EDGAR Filing Document

**Accession Number:** 0001824293
**File Stem:** 0001824293-26-000030
**Filing Date:** 2026-1
**Character Count:** 16813
**Document Hash:** d622cd570150d4d7b5c83499fdec78ed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001824293-26-000030.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001824293-26-000030

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20260129

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260129

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GRI Bio, Inc.
- **CENTRAL INDEX KEY:** 0001824293
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824369909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40034
- **FILM NUMBER:** 26580062

**BUSINESS ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (619) 400-1171

**MAIL ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRI BIO, Inc.
- **DATE OF NAME CHANGE:** 20230424

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vallon Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20200910

?xml version='1.0' encoding='ASCII'? val-20260129

![Image_0.jpg](val-20260129_g1.jpg)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549 FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 29, 2026

![Image_8.jpg](val-20260129_g2.jpg)

**GRI BIO, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40034** | **82-4369909** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
| of incorporation) | | |

---

**2223 Avenida de la Playa, #208**

**La Jolla, CA 92037**

(Address of principal executive offices and zip code)

**(619) 400-1170**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

![Image_8.jpg](val-20260129_g2.jpg)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common Stock, par value $0.0001 per share | &nbsp;&nbsp;&nbsp;&nbsp;GRI | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

![Image_0.jpg](val-20260129_g1.jpg)

![Image_8.jpg](val-20260129_g2.jpg)

------

**Item 1.01 Entry into a Material Definitive Agreement.**

As previously reported, on May 20, 2024, GRI Bio, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), pursuant to which the Company may from time to time issue and sell through Wainwright, acting as the Company's sales agent, shares of the Company's common stock, par value $0.0001 per share (the "Shares") (the "ATM Offering"). In connection therewith, on May 20, 2024, the Company filed with the Securities and Exchange Commission (the "Commission") a prospectus supplement (File No. 333-279348), related to the ATM Offering.

On January 29, 2026, the Company entered into an Amendment No. 1 to At The Market Offering Agreement (the "Amendment") with Wainwright, effective as of January 28, 2026, to increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering from $10,000,000 to up to the dollar amount of Shares registered on the prospectus supplement pursuant to which the ATM Offering is being made. In connection with the Amendment, on January 29, 2026, the Company filed a prospectus supplement with the Commission to increase the maximum number of Shares issuable in the ATM Offering to up to an aggregate of $60,000,000. Certain provisions of that Securities Purchase Agreement, dated December 11, 2025, by and between the Company and the investor set forth therein have been waived to permit issuances pursuant to the Sales Agreement, as amended by the Amendment.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text thereof, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to the legality of the issuance and sale of the Shares.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 5.1 | <u>[Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.](gri-atmx51opinionjanuary29.htm)</u> |
| 10.1 | <u>[Amendment No. 1 to At The Market Offering Agreement, dated as of January 29, 2026, between GRI Bio, Inc. and H.C. Wainwright & Co., LLC](gri-atmx8xkex101amendmentn.htm)</u> |
| 23.1 | <u>[Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (contained in Exhibit 5.1).](gri-atmx51opinionjanuary29.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 29, 2026 | **GRI BIO, INC.** | **GRI BIO, INC.** |
|  | By: | /s/ Leanne Kelly |
|  | Name: | Leanne Kelly |
|  | Title: | Chief Financial Officer |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![image_1.jpg](image_1.jpg) | 3580 Carmel Mountain Road, Suite 300<br>San Diego, CA 92130<br>858-314-1500<br>www.mintz.com |

---

January 29, 2026

GRI Bio, Inc.

2223 Avenida de la Playa, #208

La Jolla, California 92037

Ladies and Gentlemen:

&nbsp;&nbsp;&nbsp;&nbsp;We have acted as counsel to GRI Bio, Inc., a Delaware corporation (the "***Company***"), with respect to certain matters in connection with the Registration Statement on Form S-3 (File No. 333-279348) (the "***Registration Statement***"), filed with the Securities and Exchange Commission (the "***Commission***") under the Securities Act of 1933, as amended (the "***Act***"), the related prospectus dated May 16, 2024 included within the Registration Statement (the "***Base Prospectus***") and the prospectus supplement dated January 29, 2026, relating to the issue and sale of up to $60,000,000 of shares of the Company's common stock, par value $0.0001 per share (the "***Shares***"), each filed with the Commission pursuant to Rule 424(b) promulgated under the Act (together with the Base Prospectus, the "***Prospectus***"). The Shares are to be sold by the Company in accordance with that certain At the Market Offering Agreement, dated May 20, 2024, between the Company and H.C. Wainwright & Co., LLC, as amended by Amendment No. 1 to At The Market Offering Agreement, dated January 29, 2026 and effective as of January 28, 2026 (the "***Sales Agreement***"), as described in the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;In connection with this opinion, we have examined the Company's Amended and Restated Certificate of Incorporation, as amended to date, and Amended and Restated Bylaws, both as currently in effect, such other records of the corporate proceedings of the Company and certificates of the Company's officers as we have deemed relevant, as well as the Registration Statement and the exhibits thereto and the Prospectus.

&nbsp;&nbsp;&nbsp;&nbsp;In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies.

&nbsp;&nbsp;&nbsp;&nbsp;Based upon the foregoing, and subject to the limitations set forth below, we are of the opinion that the Shares, when issued by the Company out of the Company's duly authorized common stock and issued and delivered by the Company against payment therefor as contemplated by the Sales Agreement, on terms approved by the Board of Directors of the Company, or a duly authorized committee thereof, will be duly and validly issued, fully paid and nonassessable.

Our opinion is limited to the General Corporation Law of the State of Delaware, and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with respect to the qualification of the Shares under the securities or blue sky laws of any state or any foreign jurisdiction.

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible.

BOSTON&nbsp;&nbsp;&nbsp;&nbsp;LOS ANGELES&nbsp;&nbsp;&nbsp;&nbsp;MIAMI&nbsp;&nbsp;&nbsp;&nbsp;NEW YORK&nbsp;&nbsp;&nbsp;&nbsp;SAN DIEGO&nbsp;&nbsp;&nbsp;&nbsp;SAN FRANCISCO&nbsp;&nbsp;&nbsp;&nbsp;TORONTO&nbsp;&nbsp;&nbsp;&nbsp;WASHINGTON

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

------

**MINTZ**

January 29, 2026

&nbsp;&nbsp;&nbsp;&nbsp;Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act and to the use of this firm's name therein and in the Prospectus under the caption "Legal Matters." In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.

Very truly yours,

<u>/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</u>

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

## Exhibit 10.1

**Exhibit 10.1**

**GRI BIO, INC.** 

**AMENDMENT NO. 1 TO AT THE MARKET OFFERING AGREEMENT** 

January 29, 2026

H.C. Wainwright & Co., LLC

430 Park Avenue

New York, NY 10022

Ladies and Gentlemen:

Reference is made to the At the Market Offering Agreement, dated May 20, 2024 (the "**<u>Sales Agreement</u>**"), by and between GRI Bio, Inc., a Delaware corporation (the "**<u>Company</u>**"), and H.C. Wainwright & Co., LLC (the "**<u>Manager</u>**"). Capitalized terms used herein but not otherwise defined are used herein as defined in the Sales Agreement.

The Company and the Manager (collectively, the "**<u>Parties</u>**") wish to amend the Agreement, effective as of January 28, 2026, pursuant to Section 14 of the Sales Agreement, on the terms and conditions set forth in this letter (this "**<u>Amendment</u>**"). Therefore, for and in consideration of the mutual covenants and agreements herein contained, and contained in the Sales Agreement, the Company, on the one hand, and the Manager, on the other hand, the Parties therefore hereby agree as follows:

1. <u>Sale and Delivery of Shares</u>. The first paragraph of Section 2 of the Agreement is hereby amended and restated in its entirety to read as follows:

<u>"Sale and Delivery of Shares</u>. The Company proposes to issue and sell through or to the Manager, as sales agent and/or principal, from time to time during the term of this Agreement and on the terms set forth herein, up to such number of shares (the "<u>Shares</u>") of the Company's common stock, $0.0001 par value per share ("<u>Common Stock</u>"), that does not exceed (a) the number or dollar amount of shares of Common Stock registered on the Prospectus Supplement, pursuant to which the offering is being made, (b) the number of authorized but unissued shares of Common Stock (less the number of shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company's authorized capital stock), and (c) the number or dollar amount of shares of Common Stock that would cause the Company or the offering of the Shares to not satisfy the eligibility and transaction requirements for use of Form S-3, including, if applicable, General Instruction I.B.6 of Registration Statement on Form S-3 (the lesser of (a), (b) and (c), the "<u>Maximum Amount</u>"). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 2 on the number and aggregate sales price of Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that the Manager shall have no obligation in connection with such compliance."

2. <u>Governing Law</u>. THIS AMENDMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING APPLICABLE LAW AND WAIVER OF JURY TRIAL SET FORTH IN SECTIONS 15 AND 16 OF THE SALES AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, *MUTATIS MUTANDIS*.

------

3. <u>Counterparts</u>. This Amendment may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement, which may be delivered by facsimile or in .pdf file via e-mail.

4. <u>Agreement Remains in Effect</u>. Except as provided herein, all provisions, terms and conditions of the Sales Agreement shall remain in full force and effect. As amended hereby, the Sales Agreement is ratified and confirmed in all respects. On and after the date of this Amendment, each reference in the Sales Agreement to the "Agreement", "hereinafter", "herein", "hereinafter", "hereunder", "hereof", or words of like import shall mean and be a reference to the Sales Agreement as amended by this Amendment.

(*Signature page follows.*)

------

If the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof; whereupon this instrument, along with all counterparts, will become a binding agreement by the Company and the Manager in accordance with its terms.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| GRI BIO, INC. | GRI BIO, INC. |
| By: | /s/ W. Marc Hertz, Ph.D. |
|  | Name: W. Marc Hertz, Ph.D. |
|  | Title: Chief Executive Officer |

---

---

| | |
|:---|:---|
| The foregoing Amendment No. 1 to the Sales Agreement is hereby confirmed and accepted as of the date first written above. | The foregoing Amendment No. 1 to the Sales Agreement is hereby confirmed and accepted as of the date first written above. |
| H.C. WAINWRIGHT & CO., LLC | H.C. WAINWRIGHT & CO., LLC |
| By: | /s/ Edward Silvera |
|  | Name: Edward Silvera |
|  | Title: Co-Chief Executive Officer |

---

<br>